Small molecule · Inhibitor of glutaminase (GLS) · developed by Calithera Biosciences
Phase 2Most advanced trial (none active)
What is Telaglenastat?
Telaglenastat (CB-839) is an orally bioavailable small molecule that selectively and irreversibly inhibits glutaminase, a mitochondrial enzyme that converts glutamine into glutamate. By blocking glutamine utilization, it impairs proliferation of rapidly growing, glutamine-dependent cells. It is studied in metastatic prostate cancer.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
CB-839
Drug type
Small molecule
Targets
glutaminase (GLS)
Mechanism
Inhibitor of glutaminase (GLS)
Pathways
glutamine metabolism, conversion of glutamine to glutamate
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.